Nautilus Biotechnolgy, Inc. (NAUT)

Over the past six months, Nautilus Biotechnology, Inc.'s stock price has been impacted by several events, including the release of Q3 2025 and Q4 and Fiscal Year 2025 financial results, the unveiling of the Voyager platform, the appointment of Amber Faust as Vice President of Sales, participation in several healthcare conferences, and the announcement of Baylor College of Medicine as the first Early Access Program customer. The stock has experienced significant volatility, with a surge of over 270% in the past year and nearly 80% year-to-date as of early April 2026. Guggenheim also raised its price target to $4, maintaining a Buy rating amid platform progress.

As a development-stage life sciences company with products in an early access program, Nautilus Biotechnology, Inc. does not have explicitly defined demand seasonality. Demand is primarily driven by research and development needs, early adoption by collaborators, and the successful validation and commercialization timeline of its Nautilus Voyager Platform. The company anticipates no material revenue from its Early Access Program engagements in 2026.

Nautilus Biotechnology, Inc. is a development-stage life sciences company focused on creating a platform technology to quantify the human proteome. Their mission is to transform proteomics by democratizing access to the proteome, enabling advancements in human health and medicine. Nautilus is categorized within the analytical laboratory instrument manufacturing, Biotechnology and Life Sciences Tools and Services industries. The company's primary offering is the Nautilus Proteome Analysis Platform, an end-to-end solution comprising a high-resolution optical imaging system, consumables, and software. The platform aims to enable single-molecule analysis of proteins and proteoforms, offering comprehensive proteome coverage and detail at scale.

Nautilus Biotechnology, Inc. is headquartered in Seattle, Washington, with its research and development headquarters in San Carlos, California. In January 2023, the company expanded its footprint by opening a new office in San Diego, California.

Nautilus Biotechnology's brand reputation has been positively influenced by its progress in developing and commercializing its proteomics platform. Key events contributing to a favorable reputation include the launch of the Early Access Program, the announcement of Baylor College of Medicine as the first Early Access Program customer, the unveiling of the Voyager platform, strategic collaborations with notable institutions, and positive analyst sentiment from Guggenheim. While no specific negative events impacting brand reputation were explicitly found, the company is still in a development stage with no commercial revenue, and its platform is in early access rather than broad commercial launch.

Nautilus Biotechnology, Inc. has a mixed ownership structure, with institutional, retail, and individual investors. Approximately 45.61% of the company's stock is held by institutional investors, 32.41% by individuals, and 0.43% by other entities, with 21.39% unknown, based on the 1000 largest holdings. Major institutional owners include AH Capital Management, L.L.C., Perceptive Advisors Llc, and Vanguard Group Inc. Parag Mallick, Co-Founder and Chief Scientist, owns the most shares among individual investors.